An open-label study of aripiprazole in children with a bipolar disorder.
An open-label study of aripiprazole in children with a bipolar disorder.
复制标题
阿立哌唑治疗双相情感障碍儿童的开放标签研究。
DOI：
10.1089/cap.2010.0102
复制
发表时间：
2011
影响因子：
1.9
通讯作者：
Calabrese,JosephR
中科院分区：
文献类型：
--
作者：
Findling,RobertL;McNamara,NoraK;Youngstrom,EricA;Stansbrey,RobertJ;Frazier,ThomasW;Lingler,Jacqui;Otto,BenjaminD;Demeter,ChristineA;Rowles,BrieanaM;Calabrese,JosephR
目的：探讨阿立哌唑（APZ）治疗儿童双相情感障碍躁狂发作的疗效。方法：符合精神障碍诊断与统计手册第4版诊断标准（Young Mania Rating Scale [YMRS] score ≥15）的门诊患者，年龄4-9岁。受试者接受灵活剂量的APZ（最大日剂量为15 mg/天）前瞻性治疗，持续长达16周或达到优先反应标准。结果：96例患儿均采用YMRS、临床总体抑郁量表-严重程度、儿童总体评定量表（CGAS）和儿童抑郁量表-修订版（CDRS-R）评定，其中CDRS-R <29分、YMRS <10分、CGAS > 50分为优先反应标准（62名男性;平均年龄为6.9（SD = 1.7），接受APZ治疗的平均时间为12.5（SD = 3.9）周。在研究参与结束时，注意到YMRS、CDRS-R、CGAS和临床总体应激量表-严重程度评分的显著改善（p< 0.001）。研究结束时，60例受试者（62.5%）Meta荟萃优先反应标准。最常见的副作用是胃痛、食欲增加和头痛。2例受试者因副作用[鼻衄（n= 1）;静坐不能（n= 1）]从研究中移除。受试者经历了平均体重增加2.4（SD = 1.9）kg.Conclusion：APZ可能是有效的急性治疗儿童双相情感障碍的症状。
Objective:The purpose of this open-label study was to describe the effectiveness of aripiprazole (APZ) in the treatment of children with bipolar disorders suffering from manic symptomatology.Method:Symptomatic outpatients (Young Mania Rating Scale [YMRS] score ≥15) meeting strict, unmodified,Diagnostic and Statistical Manual of Mental Disorders, 4th edition, diagnostic symptom criteria for a bipolar disorder, ages 4–9 years, were eligible. Subjects were treated prospectively with flexible doses of APZ (maximum daily dose of 15 mg/day), for up to 16 weeks or untila prioriresponse criteria were met. Outcome measures included the YMRS, Clinical Global Impressions Scale-Severity, Children's Global Assessment Scale (CGAS), and the Children's Depression Rating Scale-Revised (CDRS-R).A prioriresponse criteria consisted of 3 of 4 consecutive weeks with (1) CDRS-R <29; (2) YMRS <10; and (3) CGAS >50.Results:Ninety-six children (62 males; mean age of 6.9 (SD = 1.7), received APZ for an average length of treatment of 12.5 (SD = 3.9) weeks. Significant improvements in YMRS, CDRS-R, CGAS, and Clinical Global Impressions Scale-Severity scores (p< 0.001) were noted at the end of study participation. Sixty of the subjects (62.5%) meta prioriresponse criteria at study's end. The most common side effects noted were stomachache, increased appetite, and headache. Two subjects were removed from the study due to side effects [epistaxis (n= 1); akathisia (n= 1)]. Subjects experienced an average weight gain of 2.4 (SD = 1.9) kg.Conclusion:APZ may be effective in the acute treatment of symptoms of children with bipolar illnesses.